Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, as of 2/13/18, the trial has been opened at 4 centers and 8 patients have been enrolled.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.